Kevirx Inc.

Charlottesville, VA

UEI
UYB4K2ZUBD18
CAGE
7PGF5
Primary NAICS
Not on record
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Website
kevirx.com
Founded
2016
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Developing KVX-053, a PTP4A3-targeted small molecule inhibitor, for acute lung injury HT94252410284 Defense Health Agency $1,991,213
A PTP4A3 inhibitor for SARS-COV-2-mediated acute lung injury - the severe acute respiratory syndrome coronavirus… R43HL158409 National Heart Lung and Blood Institute (NIH) $313,708
Developing small molecule PTP4A3 inhibitors for ovarian cancer R43CA228774 National Cancer Institute (NIH) $289,307

Similar vendors

Vendor Location Primary NAICS
Medchem Partners LLC UEI S93ZFQLD4ZC7 Lexington, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Akanocure Pharmaceuticals Inc. UEI QMU8ZFLN2A34 West Lafayette, IN —
Creative Biotherapeutics LLC UEI YNJ8ST14PBD8 Gurnee, IL —
Proteogenomics Research Institute For Systems Medicine UEI EAZXZLPJYJZ2 San Diego, CA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Senex Biotechnology Inc. UEI G8XKMW3DYMQ6 Maynard, MA 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Kevirx Inc. is a for-profit organization that has been registered in SAM.gov since August 2016 to receive federal grants and contracts. They primarily focus on developing small molecule inhibitors for various medical applications, including acute lung injury, COVID-19-related respiratory issues, and ovarian cancer.

Through recent federal grant awards, Kevirx Inc. has received funding from agencies such as the Defense Health Agency, the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute, and the NIH National Cancer Institute. In 2024, they secured a $1,991,213 project grant from the Defense Health Agency to develop KVX-053, a PTP4A3-targeted small molecule inhibitor, for the treatment of acute lung injury in military and battlefield settings. Additionally, in 2021, Kevirx Inc. received a $941,124 NIH grant to investigate the potential of KVX-053 in mitigating acute lung injury and cytokine storms associated with SARS-CoV-2 infection and COVID-19. Another NIH grant awarded in 2019, worth $289,307, supported their research on developing small molecule PTP4A3 inhibitors for ovarian cancer treatment. Across these grants, Kevirx Inc. has demonstrated expertise in developing targeted small molecule inhibitors for various medical applications, particularly in the areas of acute lung injury, respiratory diseases, and cancer therapeutics.

Quick answers

Is Kevirx Inc. registered in SAM.gov?

Kevirx Inc.'s SAM.gov registration expired on October 28, 2026.

What is Kevirx Inc.'s CAGE code?

Kevirx Inc.'s CAGE code is 7PGF5, and its Unique Entity ID (UEI) is UYB4K2ZUBD18.

What is Kevirx Inc.'s most recent federal award?

Kevirx Inc.'s most recent federal grant award is Developing KVX-053, a PTP4A3-targeted small molecule inhibitor, for acute lung injury (HT94252410284), from Defense Health Agency, on April 9, 2024.

On GovTribe

See Kevirx Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe